H.C. Wainwright Maintains Buy on APRE Aprea Therapeutics Inc March 2026

H.C. Wainwright maintained a Buy rating on Aprea Therapeutics, Inc. (APRE) on March 16, 2026, marking the latest APRE analyst rating update. The firm highlighted clinical progress for APR-1051, noting 50% lesion reduction in endometrial cancer, while the stock showed a -4.04% move since the note. The update did not include a new price target and listed Price at Time as N/A. This APRE analyst rating keeps H.C. Wainwright among the primary public followers of the company.